It was just before an early morning meeting, and I was really trying to get to the bagels, but I couldn't help overhearing a conversation between one of my statistical colleagues and a surgeon.

A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk of false-negative ...